The 12 closest competitors and alternatives to Haya Therapeutics SA among biotechnology companies — ranked by similarity to what Haya Therapeutics SA actually does, not by market-cap band.
Subscribe to see Haya Therapeutics SA’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
HAYA Therapeutics is a precision medicines company developing RNA-guided therapeutics to target regulatory genomic dark matter for serious diseases. The company maintains dual roots with headquarters in Lausanne, Switzerland and a U.S. location in San Diego, California. It operates as a privately held biotech innovator.
Haya Therapeutics SA is a biotechnology company headquartered in Switzerland. It has raised at least $90M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $65M in May 2025. Xcout tracks 11 named people at Haya Therapeutics SA, including Eric Adam (Chief Operating Officer (COO)).
5 more named people on record for Haya Therapeutics SA, with roles, board committees and tenure — see the full roster →
At least $90M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $65M | 12 named | |
| Series A | $25M | 12 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Ranked by semantic similarity — how close each company is to Haya Therapeutics SA by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Tyra Biosciences is a biotechnology company headquartered in Carlsbad, California, that develops next-generation precision medicines.
Biotech
Rejuvenate Bio, Inc. is a biotechnology company founded in 2019 and headquartered in San Diego, United States, specializing in innovative gene therapy applications.
Life Sciences
Iris Medicine is an early-stage life sciences and biotechnology company pioneering allele-selective RNA therapies. Headquartered in California, the company develops novel treatments utilizing its proprietary sbRNA technology platform.
Similar biotechnology company
Nerai Bioscience AG is a biotechnology company headquartered in Zurich, Switzerland, that is focused on redefining genetic medicine.
Biotech
Encoded Therapeutics is a biotechnology company headquartered in South San Francisco, California, dedicated to developing next-generation genetic medicines designed to address the root causes of genetic diseases.
Biotech
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Similar biotechnology company
Enlaza Therapeutics, Inc. is a biotechnology enterprise headquartered in California, United States. The company designs and develops next-generation covalent biologic therapeutics targeting serious diseases. It utilizes specialized proprietary discovery platforms to advance precision medicine applications.
Similar biotechnology company
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Biotech
Mirador Therapeutics, Inc. is a clinical-stage precision medicine company headquartered in San Diego, California, focused on developing first- and best-in-class next-generation therapeutics.
Similar biotechnology company
Alterome Therapeutics, Inc. is a clinical-stage precision oncology company headquartered in San Diego, California, founded in 2021. The privately held biotech firm focuses on developing targeted therapies to address genomically defined cancer drivers and intractable oncological targets.
Similar biotechnology company
Neuron23 is a biotechnology company founded in 2018 that focuses on developing precision therapeutics for genetic diseases. Headquartered in South San Francisco, California, the company relies on a team of scientific experts and entrepreneurs.
Biotech
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Search any company we track to see its competitive set.
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Haya Therapeutics SAand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →